Mechanisms utilized by feline adipose-derived mesenchymal stem cells to inhibit T lymphocyte proliferation. by Taechangam, Nopmanee et al.
UC Davis
UC Davis Previously Published Works
Title
Mechanisms utilized by feline adipose-derived mesenchymal stem cells to inhibit T 
lymphocyte proliferation.
Permalink
https://escholarship.org/uc/item/740887t1
Journal
Stem cell research & therapy, 10(1)
ISSN
1757-6512
Authors
Taechangam, Nopmanee
Iyer, Smita S
Walker, Naomi J
et al.
Publication Date
2019-06-25
DOI
10.1186/s13287-019-1300-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Mechanisms utilized by feline adipose-
derived mesenchymal stem cells to inhibit
T lymphocyte proliferation
Nopmanee Taechangam1,3, Smita S. Iyer1, Naomi J. Walker1,3, Boaz Arzi2,3 and Dori L. Borjesson1,3*
Abstract
Background: Feline adipose-derived mesenchymal stem cells (ASCs) have been successfully used in clinical trials
for the treatment of immune-mediated diseases with T cell dysregulation. However, the immunomodulatory
pathways utilized by feline ASCs to suppress T cell activation have not been fully determined. We investigated the
mechanisms used by feline ASCs to inhibit T cell proliferation, including the soluble factors and the cell-cell contact
ligands responsible for ASC-T cell interaction.
Methods: The immunomodulatory activity of feline ASCs was evaluated via cell cycle analysis and in vitro mixed
leukocyte reaction using specific immunomodulatory inhibitors. Cell-cell interactions were assessed with static
adhesion assays, also with inhibitors.
Results: Feline ASCs decrease T cell proliferation by causing cell cycle arrest in G0–G1. Blocking prostaglandin (PGE2),
but not IDO, partially restored lymphocyte proliferation. Although PDL-1 and CD137L are both expressed on activated
feline ASCs, only the interaction of intercellular adhesion molecule 1 (ICAM-1, CD54) with its ligand, lymphocyte
function-associated antigen 1 (LFA-1, CD11a/CD18), was responsible for ASC-T cell adhesion. Blocking this interaction
reduced cell-cell adhesion and mediator (IFN-γ) secretion and signaling.
Conclusions: Feline ASCs utilize PGE2 and ICAM-1/LFA-1 ligand interaction to inhibit T cell proliferation with a resultant
cell cycle arrest in G0–G1. These data further elucidate the mechanisms by which feline ASCs interact with T cells, help
define appropriate T cell-mediated disease targets in cats that may be amenable to ASC therapy, and may also inform
potential translational models for human diseases.
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Background
Mesenchymal stem cells (MSCs) are a heterogeneous,
multipotent stromal cell population, capable of proliferat-
ing in vitro as plastic-adherent cells with fibroblast-like
morphology and differentiating into bone, cartilage, and
adipose cells [1]. Aside from their regenerative properties,
MSCs also possess immunomodulatory properties and
have been used extensively to treat a wide variety of
immune-mediated diseases, both in human and veterinary
medicine [2]. In veterinary medicine, adipose-derived
mesenchymal stem cells (ASCs) have been successfully
used to treat cats with feline chronic gingivostomatitis
(FCGS), a severe debilitating oral immune-mediated dis-
ease [3, 4], but the mechanisms by which feline ASCs
modulate the immune system have not been fully
elucidated.
MSCs can be immunosuppressive and can inhibit the
mitogen-induced response of naïve T lymphocytes [5],
both CD4+ and CD8+, as well as of natural killer (NK)
cells [6]. There are several possible mechanisms by
which MSCs may inhibit T lymphocyte proliferation in-
cluding the induction of apoptosis, cell cycle arrest, in-
duction of a phenotype switch to regulatory T cells, or
decreasing T lymphocyte activation, ultimately leading
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to anergy [7]. Suppression of T cell proliferation by
MSCs can be mediated by secreted soluble factors be-
cause the separation of MSCs and activated T lympho-
cytes by a transwell can inhibit proliferation without the
presence of cell-cell contact [8, 9]. However, direct cell-
cell contact is also important in MSC regulation of T
lymphocyte function in both humans and cats [8, 10].
MSC immunosuppressive functions require preliminary
activation by immune cells through the secretion of IFN-γ,
a pro-inflammatory cytokine [6, 11]. Activated feline ASCs
secrete high levels of immunomodulatory mediators, in-
cluding indoleamine 2,3 dioxygenase (IDO), prostaglandin
E2 (PGE2), interleukin (IL)-6, IL-8, and transforming
growth factor beta (TGFβ) similar to human MSCs. How-
ever, unlike human MSCs, the secretion of PGE2 and IDO
by feline ASCs is significantly reduced in the absence of
direct-cell contact [8]. In contrast to other species, includ-
ing humans, dogs, and horses, feline ASCs inhibit lympho-
cyte proliferation in the context of significantly increased
concentration of IFN-γ [8, 12, 13].
Several cell ligand pairs have been implicated in MSC
and T lymphocyte adhesion and signaling that subse-
quently impact the secretion of soluble immunomodula-
tory factors. These ligand pairs include ICAM-1/LFA-1,
VCAM-1/VLA-4, and PDL-1/PD-1 [14, 15]. In murine
MSCs, ICAM-1 is a requirement for lymphocyte–MSC
adhesion and blocking ICAM-1 ligand reduced T cell ac-
cumulation around MSCs and reversed the suppression of
lymphocyte proliferation [15]. ICAM-1 also plays a crucial
role, particularly in T cell interactions with antigen-
presenting cells, and is essential for the immunosuppres-
sive effects of murine bone marrow-derived MSCs [15,
16]. PDL1 and PDL-1, a negative costimulatory molecule,
has also been implicated in contact-dependent suppres-
sion in human MSCs [14, 17].
Our data from in vivo studies suggest that one mechan-
ism by which feline ASCs decrease T cell-mediated inflam-
mation is via the induction of CD8+ regulatory T cells [4].
Other groups have shown that CD137-CD137L co-
stimulation can induce CD8+ regulatory T cells in the
presence of IFN-γ [8, 18, 19]. Co-stimulation through the
CD137-137L pathway also enhances suppressive T cell
function and induces activated T cell anergy in human
immune-mediated diseases [20, 21].
The purpose of this study was to define the mechanisms
used by feline ASCs to suppress T lymphocyte prolifera-
tion, focusing on both soluble mediators and direct cell-
cell contact ligands. Similar to human ASCs, we found that
(1) feline ASCs induce G0–G1 cell cycle arrest in mitogen-
activated T lymphocytes, (2) PGE2 is a primary soluble fac-
tor partially responsible for the inhibition of T lymphocyte
proliferation, and (3) a crucial ligand pair mediating feline
ASC and T lymphocyte adhesion and secretion profile is
ICAM-1/LFA-1. Notably, the increase in IFN-γ secretion
induced after feline ASC-T cell direct interaction is abro-
gated when ICAM-1 is blocked. These findings shed light
on both shared and unique aspects of feline ASC biology
that may underscore how the administration of ASCs re-
sults in long-term reprograming of the immune system in
cats with FCGS.
Materials and methods
Feline adipose-derived mesenchymal stem cells (ASCs)
Low passage (P1–P5) adipose-derived feline mesenchymal
stem cells (ASCs) were isolated from subcutaneous feline
adipose tissue surgically obtained from specific pathogen-
free (SPF) cats or from client-owned cats undergoing rou-
tine surgery. Fat collection was conducted according to a
protocol approved by the Institutional Animal Care and
Use Committee, and the Clinical Trials Review Board,
UCD (protocol number 18422). All owners of client-
owned cats signed an informed consent form. All cats
were free of feline immune deficiency virus and feline
leukemia virus infection. ASC isolation and expansion was
performed at the UC Davis William R. Pritchard Veterin-
ary Medical Teaching Hospital Regenerative Medicine La-
boratory, exactly as previously described [4].
ASC culture and expansion
Feline ASCs were expanded as previously described [22].
In brief, cryopreserved ASCs were thawed in a 37 °C water
bath and seeded into tissue culture flasks with Dulbecco’s
modified Eagle’s medium (DMEM; Corning Life Sciences),
10% fetal bovine serum (HyClone Inc.), and 1% penicillin/
streptomycin (Thermo Fisher Scientific) and incubated at
37 °C in 5% CO2 at 90% humidity. Feline ASCs from pas-
sages 2–5 were used in the experiments. All ASC lines
passed quality control assays including bacterial culture
(all were sterile), high viability (> 90%), positive for CD90
(identity marker), negative for CD18 (purity marker), and
negative for endotoxin and Mycoplasma.
Peripheral blood monocular cell (PBMC) inhibition
assay—mixed leukocyte reaction (MLR)
Feline ASCs were tested for their capability to inhibit
lymphocyte proliferation with a mixed leukocyte reaction
(MLR), carried out as previously described [4]. In brief,
PBMCs were isolated from whole blood using gradient cen-
trifugation and were co-incubated with irradiated ASCs in
culture wells at a 1:5 (PBMC to ASC) ratio and activated
with 5mg/mL concanavalin A (ConA; Sigma-Aldrich).
Cells were co-cultured for 4 days. Control wells included
PBMCs alone and ConA-stimulated PBMCs. To determine
indoleamine 2,3-dioxygenase (IDO) activity, the experiment
was run as described; however, the media was supple-
mented with l-tryptophan (Sigma-Aldrich) to a final con-
centration of 600 μM. To measure proliferation, wells were
spiked with 5-bromo-29-deoxyuridine (BrdU) at day 3 and
Taechangam et al. Stem Cell Research & Therapy          (2019) 10:188 Page 2 of 12
then cells were collected and processed per manufacturer’s
instructions (BrdU Flow Kit; BD Biosciences) at day 4.
Some protocols included the addition of antibodies to
block TGF-β (10 μg/mL, anti TGF-β1 mouse monoclonal
IgG, clone 9106, R&D systems), or interferon gamma (IFN-
γ, 15 μg/mL, goat anti-feline polyclonal antibody #AF674,
R&D systems), or chemicals to block prostaglandin E2
(PGE2, 10 μm/mL, indomethacin, Cayman Chemical), or
IDO (500 μM/mL 1-methyl-L-tryptophan (Sigma-Aldrich),
a competitive inhibitor of tryptophan). Inhibitor concentra-
tion was determined by titration studies in our laboratory
or based on previous publications [23].
Feline ASCs and PBMC phenotyping
For the analysis of surface expression on feline ASCs and
PBMCs, cells were harvested and resuspended at a concen-
tration of 1 × 106 cell/mL in flow buffer (DPBS, 1% normal
equine serum, 10mM EDTA, and 0.1% sodium azide).
Cells were incubated with antibodies for 30min at room
temperature. Antibodies included mouse anti-feline CD4-
PE (clone 3-4F4, Southern Biotech), mouse anti-feline
CD5-FITC (clone f43, Southern Biotech), mouse anti-feline
CD8α-PE (clone Fe1.10E9, Leukocyte Antigen Biology La-
boratory, UC Davis), mouse anti-human I-CAM 1 (CD54,
clone MEM-111, Thermo Fisher Scientific), rat anti-mouse
CD137L (clone TKS-1, Bio X Cell), polyclonal goat anti-
human-PD-1 (cat#AF1086, R&D systems), polyclonal goat
anti-human-PDL-1/B7-H1 (cat#AF156, R&D systems).
The secondary antibody used for indirect labeling was R-
Phycoerythrin F(ab’)2 Fragment donkey anti-goat IgG
(Jackson ImmunoResearch Inc.) and Fluorescein Rabbit
Anti-Rat IgG (Vector Laboratories). Cells were analyzed
with a Beckman-Coulter Cytomics FC500 flow cytometer.
Data analyses were done on Flowjo flow cytometry soft-
ware (Tree Star, Inc.).
Cell cycle analysis
Lymphocyte DNA content was determined with 7-amino-
actinomycin D (7-AAD; BD Biosciences) incorporation to
distinguish between lymphocyte populations in the S-
phase, G1 phase, and G2–M phase in conjunction with
BrdU incorporation (FITC BrdU Flow Kit; BD Biosciences).
PBMCs were collected for 4 consecutive days from co-
incubation experiments with feline ASCs. Cells were
analyzed with a Beckman-Coulter Cytomics FC500 flow
cytometer. Data analyses were done on Flowjo flow cytom-
etry software (Tree Star, Inc.).
Detection of intracellular IFN-γ
PBMCs were collected from the MLR on day 4 and resus-
pended in RPMI 1640 media with 10% heat-inactivated
FBS, 1% Gluta-Max, 1mM sodium pyruvate, 1%
penicillin-streptomycin, 2 mM HEPES, 0.1% MEM NEAA,
and 55 μM β-mercaptoethanol. Collected cells were
stimulated with 25 ng/mL Phorbol-12-Myristate-13-Acet-
ate (PMA, Sigma-Aldrich) and 500 ng/mL ionomycin
(Sigma-Aldrich), treated with 1 μg/mL Brefeldin A and in-
cubated for 3 h at 37 °C. Cells were then washed, stained
with a viability dye (Fixable Viability Dye eFlour®780,
eBioscience), fixed with 2% paraformaldehyde, perme-
abilized in wash buffer (DPBS with 0.5% bovine serum al-
bumin, 0.1% saponin, and 0.02% sodium azide), and
stained with anti-bovine IFN-γ-AlexaFluor647 antibody
(clone CC302, Bio-Rad). Cells were analyzed with
Beckman-Coulter Cytomics FC500 flow cytometer. Data
analyses were done on Flowjo flow cytometry software
(Tree Star, Inc.).
Detection of secreted mediators
IDO, nitric oxide (NO), PGE2, and IFN-γ were measured
in the MLR culture supernatant collected on day 4. Super-
natants were stored at − 80 °C until analyzed. PGE2 and
IFN-γ concentration were measured using commercially
available feline-specific ELISA kits (Enzo Life Sciences and
R&D systems, respectively), according to the manufac-
turer’s instructions [8]. IDO activity was determined
through the measurement of colorimetric kynurenine
level assay, and NO was measured with a Griess reagent
system (Griess Reagent System, Promega Corporation),
both performed exactly as previously described [12]. All
samples were read on a Synergy HT Multi-Mode micro-
plate reader with Gen5 software (Biotek).
MSC-PBMC static adhesion assay
Static adhesion assay was modified from Ren et al. [15]. In
brief, feline ASCs were plated in 24-well plates (5 × 104
cells/well) in 750 μL standard culture medium. Isolated
PBMCs were fluorescently labeled with CellTracker™
Green CMFDA (5-chloromethylfluorescein diacetate,
Thermo Fisher Scientific) and activated with 5 μg ConA
for 1 h prior to adding to the ASCs (1 × 106 cells/well).
Cells were permitted to adhere to ASCs for 2 h at 37 °C in
5% CO2. The plates were then rotated at 300 rpm for 5
min and washed with DPBS twice to remove non-attached
PBMCs. Fluorescence was detected using a Synergy HT
Multi-Mode microplate reader at 485-nm wavelength
prior to and after washing to quantify the change in fluor-
escent intensity. The plate was also visualized and photo-
graphed on an inverted fluorescent microscope (EVOS
FL, Thermo Fisher Scientific). In some experiments,
blocking antibodies to ICAM 1 (anti-human CD54, clone
MEM-111, Thermo Fisher Scientific), LFA-1 (anti-human
clone R7.1, eBioscience), CD137 (anti-mouse clone 17B5,
Bio X Cell), CD137L (anti-mouse clone TKS-1, Bio X
Cell), PD-1 (anti-human PD-1, polyclonal goat IgG, R&D
systems), or PDL-1 (anti-human PDL-1, polyclonal goat
IgG, R&D systems) were added to determine which li-
gands mediated PBMC-ASC adhesion. The concentration
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of antibodies used was determined by titration studies in
our laboratory.
Statistical analyses
Data analysis was performed using GraphPad Prism ver-
sion 7 software (GraphPad Software). All experiments
were performed with n = 5 (feline ASC lines and PBMCs
donors) unless otherwise indicated. Statistical significance
between two groups was determined by non-parametric
Mann-Whitney-Wilcoxon test due to small sample size. p
values < 0.05 were considered statistically significant.
Results
Activated feline CD4+ and CD8+ T lymphocytes both
secrete IFN-γ
Feline ASCs decrease activated T cell proliferation and se-
cretion of pro-inflammatory cytokines, notably tumor
necrosis factor alpha (TNF-α). However, unlike other spe-
cies, including people, dogs, and horses, feline ASCs inhibit
lymphocyte proliferation in the presence of increased IFN-
γ concentration when ASCs are in direct contact with lym-
phocytes [6, 8, 12, 13, 24]. We previously hypothesized that
feline ASCs could be licensed by IFN-γ and this signaling
may be critical for the long-term reprograming of CD8+
regulatory T lymphocytes [25–27]. Our previous work did
not identify the cell types responsible for IFN-γ secretion
in our assays. As ASCs inhibit lymphocyte proliferation re-
gardless of cell-cell contact, high IFN-γ concentration can
be used as a surrogate marker of contact-mediated T cell
inhibition and the reduction of IFN-γ secretion can be
used as a marker of effective blockade of this pathway.
We found that feline CD4 and CD8 T lymphocytes
both secrete IFN-γ after mitogen activation (Fig. 1a–d)
and the secretion of IFN-γ from CD4+ T lymphocytes is
significantly increased upon co-incubation with feline
ASCs (p = 0.02; Fig. 1g), and the level of IFN-γ is sus-
tained with a tendency to increase in CD8+ T lympho-
cytes in the presence of feline ASCs (Fig. 1h).
A B
G
H
C D
E F
Fig. 1 Both activated feline CD4 and CD8+ T cells secrete IFN-γ. Intracellular IFN-γ+ cell population in a unstimulated CD4+ cells, b unstimulated CD8+
cells, c CD4+ cells stimulated with ConA, d CD8+ cells stimulated with ConA, e CD4+ cells in co-incubation with feline ASCs, and f CD8+ cells in co-
incubation with feline ASCs. g Percentage of IFN-γ+CD4+ T cell increased after mitogen activation (p= 0.008) and was further augmented with feline ASC
co-incubation (p= 0.02) h Percentage of IFN-γ+CD8+ T cell increased after mitogen activation (p= 0.02) with a trend to increase with feline ASC co-
incubation, but was not statistically significant. Representative flow cytometric images and data from 5 independent experiments. *p< 0.05
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Feline ASCs decrease activated PBMC viability and inhibit
lymphocyte proliferation through the induction of G0–G1
cell cycle arrest
Feline ASCs inhibit mitogen-activated T cell proliferation
with and without the presence of cell-to-cell contact [8],
but the mechanism of action is not known. Here we dem-
onstrate that feline PBMC viability decreased upon mito-
gen activation (p = 0.04) and was even further exacerbated
by the co-incubation with feline ASCs (p = 0.008; Fig. 2a–
d). Additionally, cell cycle analysis revealed that the per-
centage of T lymphocytes in the G0–G1 phase increased
with a concurrent decrease in the S-phase upon co-
incubation with feline ASCs (p = 0.03). However, feline
ASCs did not undergo increased apoptosis compared to
the mitogen-activated condition (Fig. 2d–f). These findings
suggest that feline ASCs inhibit activated PBMC viability
and inhibit the proliferation of mitogen-activated T lym-
phocytes through the induction of G0–G1 cell cycle arrest.
Feline ASC secretion of PGE2 is partially responsible for
inhibiting lymphocyte proliferation
Our previous data suggested that there are at least 2
mechanisms by which feline ASCs inhibit activated T
cell proliferation, one relying on direct contact between
the ASCs and T lymphocytes and another dependent on
soluble factors [3, 8]. Feline ASCs constitutively produce
low concentrations of immunomodulatory mediators in
the absence of activation, but secretion is much higher
in the presence of mitogen-activated T cells, particularly
the secretion of IDO and PGE2 which is enhanced by
direct cell contact [8]. Although the feline ASC secre-
tion profile has largely been determined [8], we wanted
to (1) more fully elucidate mediators secreted by feline
ASCs (in the presence and absence of contact) and (2)
identify the soluble mediators critical for the inhibition
lymphocyte proliferation, focused on TGF-β, IFN-γ,
PGE2, and IDO.
Nitric oxide (NO) may play an important role in hu-
man MSC-induced T lymphocyte immunosuppression
[28]; however, feline ASCs did not secrete substantial
quantities of NO even in the presence of activated T
lymphocytes (Fig. 3a). Like PGE2, IDO was secreted by
activated feline ASCs and PBMCs [8] but only in the
presence of direct cell-contact (p = 0.008; Fig. 3b).
We found that PGE2 was partially responsible for the
inhibition of activated lymphocytes by feline ASCs (p =
0.03); however, blocking TGF-β, IFN-γ, and IDO did not
significantly restore lymphocyte proliferation (Fig. 3c–e).
Blocking both PGE2 and IDO demonstrated a slight in-
crease, but did not significantly restore lymphocyte pro-
liferation (Fig. 3e).
A B C D
E F G H
Fig. 2 Feline ASCs decrease activated PBMC viability and induce cell cycle arrest in activated T lymphocytes. Representative images of flow cytometric
analysis on day 4 from 5 MLR experiments with condition of a PBMCs only, b mitogen-activated PBMCs, and c PBMCs in co-incubation with feline ASCs. d
the percentage of viable PBMCs decreased after mitogen activation (p= 0.04) and was further exacerbated by the co-incubation with feline ASCs (p=
0.008). Flow cytometric scatter plot of cell cycle analysis on T lymphocyte DNA content (7-AAD) and proliferation determined through BrdU incorporation
of e PBMCs only, f mitogen-activated PBMCs, and g PBMCs in co-incubation with feline ASCs. h Percentage of T cells in the apoptotic, G0–G1, S, and G2–
M phases from cell cycle analysis revealed that the percentage of T lymphocytes in the G0–G1 phase increased with a concurrent decrease in the S-phase
upon co-incubation with feline ASCs (p= 0.03). *p< 0.05 **p< 0.01
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ICAM-1 mediates the adhesion between feline ASCs and T
lymphocytes
Cell-cell contact is an important factor for MSC-mediated
T cell immunosuppression [12, 17, 29]. Given the import-
ance of cell-cell contact and the unique contact-dependent
mediator secretion profile for feline ASCs in particular, we
investigated the potential role of 3 ASC cell surface recep-
tors [CD54 ICAM-1, PDL-1, and CD137L] to regulate T
cell-feline ASC adhesion. We first determined if ICAM-1,
PDL-1, and CD137L were expressed on feline MSCs and
whether co-incubation of activated T cells with MSCs re-
sulted in increased expression of these surface receptors.
Flow cytometric analysis revealed that activated feline
ASCs expressed ICAM-1, CD137L, and PDL-1 on their
surface (Fig. 4a–c). Activated feline T cells express LFA-1
[30], PD-1 [31], and CD137 [unpublished data]; however, it
was unknown if, similar to human MSCs, ASC co-
incubation with activated T cells would decrease PD-1,
CD137, and LFA-1 expression on activated T cells. We
found that, unlike human MSCs, feline ASCs did not
decrease PD-1 expression on activated T cells (Add-
itional file 1).
We then utilized blocking antibodies against ICAM-1/
LFA-1, CD137/CD137L, and PD-1/PDL-1 to directly test
whether these ligand pairs mediated feline ASC-
lymphocyte adhesion in static conditions. Neither the
blockade of CD137/CD137L nor PD-1/PDL-1 significantly
altered T cell-ASC adhesion (Fig. 4d–j). However, blocking
ICAM-1 significantly reduced T cell-ASC adhesion to
levels comparable to adhesion between non-activated T
cells and ASCs (p = 0.045; Fig. 5a–d). Blocking ICAM-1
also resulted in a concurrent significant reduction of IFN-γ
secretion (p = 0.002; Fig. 5e). These findings collectively
suggest that ICAM-1 is important for mediating the adhe-
sion between feline ASCs and T cell and may be involved
in contact-dependent immunomodulation by feline ASCs.
Discussion
Cats are increasingly used as translational models for
MSC-based therapies, and a number of inflammatory fe-
line diseases resemble human inflammatory conditions
[32, 33]. Feline ASCs have been used in a number of clin-
ical trials for diseases including feline chronic gingivosto-
matitis (FCGS), chronic enteropathy, chronic kidney
A
C D E
B
Fig. 3 PGE2 secretion partially mediates feline ASC inhibition of T lymphocyte proliferation. a Measurement of iNOS production from supernatant of MLR
on day 4 of co-incubation. Data from 5 independent experiments. b Measurement of IDO production from supernatant of MLR on day 4 of feline ASC and
PBMC co-incubation with and without transwell. Data from 5 independent experiments. Degree of proliferation in the MLR with inhibition of soluble
mediators: c addition of TGF-β and IFN-γ blocking antibody, d blocking of PGE2 with indomethacin, e blocking IDO with 1-methyltryptophan and PGE2
with indomethacin. Percentage of proliferation is normalized to 100% on mitogen activated condition for comparability. Blocking PGE2 significantly
hindered the degree of suppression (p= 0.03). *p< 0.05, **p< 0.01
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Fig. 4 ICAM-1, CD137L, and PDL-1 are all expressed on activated feline ASCs; however, CD137L and PDL-1 do not mediate MSC-T cell adhesion.
Expression of a ICAM-1, b CD137L, and c PDL-1 ligands on activated feline ASCs. Gray histogram indicated background fluorescence of unstained samples.
d Percentage of remaining fluorescence intensity from CMFDA-labeled PBMCs after removal of non-adherent cells from static adhesion assay after the
addition of CD137/CD137L and PD-1/PDL-1 blocking antibodies. Data is normalized to 100% on a standard MLR condition for comparability. Fluorescent
images of static adhesion assay demonstrating adherent lymphocytes to ASCs from e, h non-activated MLR, f, i stimulated MLR with ConA, and g, j
stimulated MLR with ConA and addition of CD137/CD137L and PD-1/PDL-1 blocking antibodies respectively. Scale bar = 400 μm. Representative flow
analysis images in a–c from 3 independent experiments. Data gathered in d from 5 independent experiments
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Fig. 5 I-CAM 1 ligand mediates the adhesion between feline ASCs and T lymphocytes. Fluorescent images of static adhesion assay demonstrating
adherent lymphocytes to feline ASCs from a non-activated MLR, b stimulated MLR with ConA, c stimulated MLR with ConA and addition of ICAM-1
blocking antibodies, and d stimulated MLR with ConA and addition of ICAM-1/LFA-1 blocking antibodies. Scale bar = 400 μm. e Percentage of remaining
fluorescence intensity from CMFDA-labeled PBMCs after removal of non-adherent cells from static adhesion assay with added condition of ICAM-1
blocking antibodies. Data is normalized to 100% on standard MLR condition for comparability. f Changes in IFN-γ concentration in the MLR after addition
of ICAM-1 blocking antibodies. Data from 5 experiments, normalized to 100% on standard MLR condition for comparability. *p< 0.05, **p< 0.01
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disease, and feline asthma with varying degrees of success
[3, 4, 34–36]. However, the exact mechanism(s) by which
feline ASCs alter T cell responses remain vaguely under-
stood. The objective of this study was to elucidate the
underlying pathways utilized by feline ASCs to mitigate
inflammatory conditions characterized by activated T cell
proliferation.
MSCs can modulate T cell function, suppress T cell
proliferation, and decrease T cell viability, but the mech-
anisms by which they accomplish these tasks are differ-
ent between species and tissue sources. Based on our
current study, we determined that feline ASCs inhibit T
cell proliferation via cell cycle arrest in the G0–G1
phase, similar to murine BM-MSCs [37], equine BM-
and cord blood-derived MSCs [38], and canine ASCs
(unpublished data). MSCs from other tissues sources, in-
cluding equine ASCs and cord tissue-derived MSCs in-
hibit T cell proliferation through induction of apoptosis
[38]. Human MSCs cause T cell apoptosis through a path-
way mediated by IDO and IL-10 [39, 40]. Despite the
species and tissue source variation, mechanisms under-
lying MSC inhibition of T cell responses are mediated by
soluble factors and/or direct cell-to-cell interactions.
The interaction of cell surface receptors and their respect-
ive ligands on target cells are crucial for cell communication
and modulation of cell functions [41]. ICAM-1 is an indu-
cible cell adhesion glycoprotein expressed on the surface of
a wide variety of cell types, including MSCs across different
species [42]. ICAM-1 interactions with the β2 integrin
CD11a/CD18 (LFA-1) on the surface of lymphocytes are
functionally important as costimulatory molecules for T cell
activation [43]. In humans, ICAM-1 is constitutively
expressed at a low level on the MSC surface but is signifi-
cantly unregulated in the presence of pro-inflammatory cy-
tokines, such as IFN-γ [44, 45]. Here we demonstrate that
feline MSCs express ICAM-1 on their surface and that this
molecule is similarly upregulated by activation. Further, our
data demonstrate that this ligand plays a critical role in
ASC-lymphocyte adhesion and signaling.
Although feline ASCs are capable of inhibiting lympho-
cyte proliferation in the absence of direct cell contact [8],
the secretion profile of ASCs with and without direct cell-
cell contact is very different. Our current data demonstrate
that ICAM-1/LFA-1 interaction is critical for cell-cell ad-
hesion and plays an important role in the secretion of im-
munomodulatory mediators, from both T cells (IFN-γ) and
MSCs (PGE2), as blocking these ligands significantly re-
duced their concentration. Our findings mimic in vivo
findings in a mouse model where blockade of ICAM-1 lig-
and also decreased IFN-γ secretion and reduced pulmon-
ary barrier damage in T cell-induced acute lung injury [46].
In mice, it was also found that the overexpression of
ICAM-1 on MSCs can enhance the immunosuppressive
effects of MSCs, including modulating T cell responses,
dendritic cell maturation, and secretion of immunomodu-
latory soluble factors in vitro [47].
We also evaluated the ligand pairs CD137-CD137L and
PD-1/PDL-1. CD137 (4-1BB), an inducible protein
expressed on both CD4+ and CD8+ T cells, is functionally
involved in signaling T cell proliferation [48]. CD137-
CD137L interaction has been implicated as one potential
immunosuppressive mechanism used by human MSCs in
the treatment of multiple sclerosis [49]. CD137-CD137L
interaction has also been implicated for the paradoxical in-
crease in IFN-γ that supports CD8 T regulatory expansion
[50]. Similarly, programmed death-1 (PD-1) and its ligand,
PD-L1, is an important inhibitory pathway of T cell re-
sponse and has been implicated as a crucial interaction
used by human MSCs to inhibit T cell responses [14, 51].
However, our data suggest that although CD137L and
PDL-1 are expressed on activated feline ASCs, they are not
the primary mediators of ASC T cell adhesion and do not
mediate IFN-γ secretion in vitro.
Upon activation, feline ASCs secrete several immuno-
modulatory mediators, including IDO, PGE2, IL-6, IL-8,
and TGF-β [8, 29, 52]. However, the principal immuno-
modulatory mediators used by MSCs appear to vary by
species. Human MSCs primarily utilize IDO whereas ca-
nine MSCs, both bone marrow-derived and adipose-
derived, utilize TGF-β and PGE2 to suppress lymphocyte
proliferation [53–55]. With feline ASCs, we found that
blocking IDO, with 1-methyltryptophan, or adding a
TGF-β blocking antibody to the assay did not signifi-
cantly alter T cell proliferation. Like dogs and horses,
PGE2 is at least one soluble factor utilized by feline
ASCs to block T cell proliferation as blocking PGE2 with
indomethacin, a competitive inhibitor of PGE2, partially
restored T cell proliferation [12, 53]. However, the role
of PGE2 was modest compared to similar experiments
conducted with equine ASCs [38], implying that other
soluble factors are also likely involved in feline ASC-T
cell interaction. Despite a trend, blocking both PGE2 and
IDO did not significantly restore T cell proliferation
likely due to small sample size and the variability of T
cell responses to mitogens from different cat donors.
Our findings are in agreement with data from others that
used a different PGE2 inhibitor, NS-398, to reverse the im-
munosuppressive effects of feline ASCs [52]. Although ni-
tric oxide (iNOS) is implicated in the mechanism of MSC-
mediated T cell suppression by both human and murine
MSCs [28, 56], we found that feline ASCs do not produce
a substantial amount of iNOS, either with or without acti-
vation. These findings correspond to a recent study where
the level of iNOS RNA in feline ASCs was low or un-
detectable [29].
PGE2 is an eicosanoid lipid mediator which is pro-
duced by MSCs from most species, including human,
murine, canine, equine, and feline [13, 57]. Although
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PGE2 may be pro-inflammatory in some contexts, it can
also be immunosuppressive and is capable of decreasing
IL-2 production from T cells and shifting CD4+ T cells
from a predominantly cytotoxic Th1 response to a more
balanced Th2/Th17-mediated response [58]. PGE2 also
promotes the development of regulatory T cells and me-
diates their suppressive actions on effector T cells [59,
60]. These mechanisms may partially explain how feline
ASCs are successfully used to treat FCGS, an immune-
mediated inflammatory disease.
MSCs generally require licensing with IFN-γ to exert
their immunosuppressive effects [61], our study showed
that IFN-γ is produced by both CD4+ and CD8+ T lym-
phocytes upon mitogen activation and the production of
IFN-γ from both T cell subsets is further enhanced by fe-
line ASCs. These findings indicate that feline ASCs may
be appropriate for therapeutic trials for both CD4+- and
CD8+-mediated alloreactive diseases.
Conclusion
Feline ASCs utilize PGE2 and ICAM-1/LFA-1 ligand
interaction to inhibit T cell proliferation by causing cell
cycle arrest in the G0–G1 phase. While many questions
remained to be addressed, these findings provide a
deeper understanding of the underlying mechanisms in-
volved in the immunosuppression by feline ASCs and
will lead to more efficient implementations of ASC-
based therapy for the modulation of immune-mediated
inflammatory disease models.
Additional file
Additional file 1: Figure S1. Feline ASCs do not downregulate PD-1
expression on activated PBMCs. Flow analysis on PD-1 expression on activated T
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image of flow cytometry analysis from 3 different MSC lines. (DOCX 185 kb)
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